share_log

恒瑞医药(600276.SH):子公司获得药物临床试验批准通知书

Hengrui Pharmaceutical (600276.SH): The subsidiary obtained a notice of approval for clinical trials of the drug

Gelonghui Finance ·  Apr 8 03:38

Gelonghui, April 8 | Hengrui Pharmaceutical (600276.SH) announced that its subsidiaries Shanghai Shengdi Pharmaceutical Co., Ltd. and Suzhou Shengdia Biomedical Co., Ltd. have received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” for adbelimab injections and SHR-A1811 for injections, and will conduct clinical trials in the near future.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment